Related Experiment Video
Updated: Jun 29, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism
Jeanette Lahoud1,2, Josephine Jacobs1, Lauren Ratrut1
1Department of Pharmacotherapy and Pharmacy Services, University Health, San Antonio, TX, USA.
Background:
Apixaban and rivaroxaban, direct oral anticoagulants (DOACs) used for acute venous thromboembolism (VTE) treatment, require higher dose lead-in periods of 7 days and 21 days, respectively. The optimal lead-in duration for patients receiving more than 48 hours of parenteral anticoagulation (AC) is unclear. In addition, guidelines lack recommendations for high bleed-risk patients who might benefit from a shortened lead-in.
Objective:
This study aimed to evaluate the effectiveness and safety of a modified lead-in strategy, where parenteral AC counts toward shortening or eliminating the DOAC lead-in period, compared to a full lead-in strategy, where a 7-day apixaban or 21-day rivaroxaban lead-in is prescribed irrespective of parenteral AC received.
Methods:
A retrospective cohort study analyzed patients diagnosed with an acute VTE during hospitalization. Patients were grouped based on a modified versus full lead-in strategy. Primary outcomes of recurrent VTE (rVTE) and bleeding were evaluated at 90 days.
Results:
Of 101 included patients, 47 were in the modified lead-in group and 54 in the full lead-in group. Patients in the modified lead-in group had a higher risk of bleeding at baseline. Recurrent VTE occurred in 4 patients in the modified lead-in group, compared to 2 patients in the full lead-in group (9% vs 4%; P = .4129). Bleeding occurred in 10 patients in the modified lead-in group, compared to 3 patients in the full lead-in group (21% vs 6%; P = .0167).
Conclusion And Relevance:
No significant difference in rVTE was observed between groups. The modified lead-in group had a higher incidence of bleeding, possibly reflecting greater baseline risk and clinical complexity rather than the modification itself. Modified lead-in strategies may be reasonable in select patients, particularly those at high risk for bleeding; however, larger studies are needed to confirm safety and efficacy.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction